PRA Health Sciences to Report Fourth Quarter and Full Year 2020 Earnings

Rhea-AI Summary

PRA Health Sciences (NASDAQ: PRAH) will disclose its fourth-quarter and full-year 2020 results on February 25, 2021, after market close. A conference call for discussing these results will be held on February 26, 2021, at 9:00 a.m. (ET).

Analysts and investors can join the call by dialing (877) 930-8062 within the U.S. or (253) 336-7647 internationally. The company's extensive global reach includes over 75 offices and 18,100 employees, having supported over 4,000 clinical trials since 2000.

Positive

• Participation in approximately 4,000 clinical trials since 2000.
• Global reach with over 75 offices and more than 18,100 employees.

Negative

• None.

RALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 2021. The Company will also host a conference call on Friday, February 26, 2021 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 1139426. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 1139426.

A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, an audio playback of the call will be available at the same website.

ABOUT PRA HEALTH SCIENCES

PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, Africa, Australia and the Middle East and more than 18,100 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.

INVESTOR INQUIRIES: InvestorRelations@prahs.com

FAQ

When will PRA Health Sciences release its fourth quarter 2020 earnings?

PRA Health Sciences will release its fourth quarter 2020 earnings on February 25, 2021, after market close.

What time is the conference call for PRA Health Sciences' fourth quarter results?

The conference call will take place on February 26, 2021, at 9:00 a.m. (ET).

How can I access the audio replay of the PRA Health Sciences conference call?

The audio replay will be available for one week following the call by dialing (855) 859-2056 in the U.S. or (404) 537-3406 internationally.

What is the significance of PRA Health Sciences' participation in clinical trials?

PRA Health Sciences has participated in crucial trials that have led to the FDA or regulatory approvals for more than 95 drugs.